Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Alebund Pharmaceuticals Files for Hong Kong IPO, Leveraging CKD-Focused Portfolio with Commercialized Mircera and Late-Stage Hyperphosphatemia Candidates

Fineline Cube May 6, 2026
Company Deals

UCB to Acquire Candid Therapeutics for $2.2B, Gaining Best-in-Class BCMA T-Cell Engager Cizutamig for Autoimmune Diseases

Fineline Cube May 6, 2026
Company Deals

SiranBio Inks $1.005B Licensing Deal with GSK for First-in-Class siRNA Therapy SA030 Targeting ALK7 in Cardiometabolic Disease

Fineline Cube May 6, 2026
Company Deals

Teva to Acquire Emalex Biosciences for $700M, Adding Registration-Ready Tourette Syndrome Drug Ecopipam

Fineline Cube Apr 30, 2026
Company Deals

Eccogene Files Hong Kong IPO Prospectus with THR-β Agonist ECC4703 Leading Metabolic Disease Pipeline

Fineline Cube Apr 30, 2026
Policy / Regulatory

China’s NHC Establishes Regulatory Framework for Biomedical New Technologies with Interim Guiding Principles Effective May 1, 2026

Fineline Cube May 6, 2026
Company Drug

NMPA Approves Hangzhou Biosunpharma’s Bewintinib as First-Line JAK2 Inhibitor for Myelofibrosis with 62.8% Spleen Volume Response Rate

Fineline Cube May 6, 2026
Company Drug

Leads Biolabs’ Partner Dianthus Selects Sjögren’s, Lupus, and Dermatomyositis as Priority Indications for Bifunctional Autoimmune Drug LBL-047 Following $1B Licensing Deal

Fineline Cube May 6, 2026
Company Legal / IP R&D

HuidaGene Secures Patent for Innovative CRISPR-Cas12i System in China

Fineline Cube Aug 14, 2024

HuidaGene (Shanghai) Biotechnology Co., Ltd, a China-based biotech firm, has secured patent approval from the...

Company Drug

GSK Initiates Phase III Study for RSV Vaccine in China Following U.S. Approval

Fineline Cube Aug 14, 2024

GSK (NYSE: GSK), the UK-based pharmaceutical giant, has registered a Phase III bridging study for...

Company Drug

Sihuan Pharmaceutical Secures NMPA Approval for First Biosimilars of Novo Nordisk’s Diabetes Drugs

Fineline Cube Aug 14, 2024

Sihuan Pharmaceutical Holdings Group Ltd (HKG: 0460) has secured separate marketing approvals from China’s National...

Company

Gilead Buys Out Janssen’s Royalty Rights to Seladelpar for Primary Biliary Cholangitis Treatment

Fineline Cube Aug 13, 2024

Gilead (NASDAQ: GILD)’s financial report for the second quarter of 2024, followed by an earnings...

Company

Legend Biotech CEO Addresses Biosecure Act Concerns Amid Q2 2024 Earnings Report

Fineline Cube Aug 13, 2024

Legend Biotech Corporation (Nasdaq: LEGN), a leading Chinese biopharmaceutical company, has released its financial results...

Company Deals

Ocumension Therapeutics Partners with Alcon Laboratories, Secures Rights to Ophthalmic Products in China

Fineline Cube Aug 13, 2024

Ocumension Therapeutics (HKG: 1477), a biopharmaceutical company based in China, has entered into a strategic...

Company Drug

Pfizer’s Hemophilia Treatment Marstacimab Accepted for Review in China

Fineline Cube Aug 13, 2024

The China Center for Drug Evaluation (CDE) has accepted for review a market approval filing...

Company Drug

Junshi Biosciences Submits Twelfth Indication for PD-1 Inhibitor Loqtorzi in China

Fineline Cube Aug 13, 2024

Shanghai Junshi Biosciences Co., Ltd (HKG: 1877; SHA: 688180) has announced a new indication filing...

Company Drug

Nanjing Sanhome’s Oritinib Ships Widely for EGFR-mutated NSCLC Treatment in China

Fineline Cube Aug 13, 2024

Nanjing Sanhome Pharmaceutical Co., Ltd, a notable player in the pharmaceutical sector, has announced the...

Company Drug

Boehringer Ingelheim’s Zongertinib Earns Breakthrough Designation in China for HER2-Mutated NSCLC

Fineline Cube Aug 13, 2024

Boehringer Ingelheim, a leading German pharmaceutical company, has received a significant endorsement from China’s Center...

Legal / IP Policy / Regulatory

China’s SAMR Proposes Antitrust Guidelines to Regulate Pharmaceutical Industry

Fineline Cube Aug 13, 2024

The State Administration for Market Regulation (SAMR) in China has unveiled a draft proposal for...

Company Drug

IASO Biotherapeutics’ CAR-T Therapy Fucaso Gets FDA Green Light for Lupus Treatment

Fineline Cube Aug 13, 2024

IASO Biotherapeutics, a Chinese biotech firm, has received Investigational New Drug (IND) approval from the...

Company Drug

Ascendis Pharma’s Hypoparathyroidism Therapy Yorvipath Wins FDA Nod, Fills Market Gap

Fineline Cube Aug 13, 2024

This week, the U.S. Food and Drug Administration (FDA) granted market approval to Ascendis Pharma...

Company Deals

Siemens Healthineers Partners with Cedars-Sinai to Boost Medical Cooperation and Education

Fineline Cube Aug 13, 2024

Siemens Healthineers AG, a global leader in medical technology, has announced a strategic partnership with...

Company Medical Device

Artech Medical’s Balloon Cryoablation Catheter Wins NMPA Nod for Atrial Fibrillation Treatment

Fineline Cube Aug 13, 2024

Shanghai Artech Medical Technology Co., Ltd., a company known for its innovation in the medical...

Hospital

Former Hainan Medical University President Li Jingquan Expelled for Serious Disciplinary Violations

Fineline Cube Aug 13, 2024

Hainan’s disciplinary inspection committee has announced the expulsion of Li Jingquan, the former president of...

Company Drug

Pfizer’s RSV Vaccine Abrysvo Shows Strong Protection in Immunocompromised Adults, Phase III Sub-Study Reveals

Fineline Cube Aug 13, 2024

Pfizer Inc. (NYSE: PFE), a pharmaceutical titan based in the US, has announced encouraging topline...

Company Deals

TYK Medicines Inc. Targets HKD 506.3 Million in Hong Kong IPO for Drug Pipeline Expansion

Fineline Cube Aug 12, 2024

TYK Medicines Inc., a pharmaceutical company headquartered in Zhejiang, is gearing up for an initial...

Company Drug

Chinese NMPA Approves Hengrui Pharmaceuticals’ Generic Abraxane for Metastatic Pancreatic Cancer Treatment

Fineline Cube Aug 12, 2024

Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a leading pharmaceutical company in China, has announced...

Company Deals

Mindray Medical Forges Comprehensive Partnership with CUHK-Shenzhen School of Medicine

Fineline Cube Aug 12, 2024

Shenzhen Mindray Bio-Medical Electronics Co., Ltd (SHE: 300760), a prominent medical device company based in...

Posts pagination

1 … 309 310 311 … 660

Recent updates

  • NMPA Approves Hangzhou Biosunpharma’s Bewintinib as First-Line JAK2 Inhibitor for Myelofibrosis with 62.8% Spleen Volume Response Rate
  • Leads Biolabs’ Partner Dianthus Selects Sjögren’s, Lupus, and Dermatomyositis as Priority Indications for Bifunctional Autoimmune Drug LBL-047 Following $1B Licensing Deal
  • Simcere Pharmaceutical Receives NMPA Clinical Trial Approval for LRRC15-Targeting ADC SIM0613, Backed by $1.06B Ipsen Global Licensing Deal
  • Alebund Pharmaceuticals Files for Hong Kong IPO, Leveraging CKD-Focused Portfolio with Commercialized Mircera and Late-Stage Hyperphosphatemia Candidates
  • Senhwa Biosciences Launches Global Phase I/II Trial of First-in-Class Pidnarulex Combined with BeOne’s Tislelizumab in Solid Tumors Including Pancreatic Cancer
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

NMPA Approves Hangzhou Biosunpharma’s Bewintinib as First-Line JAK2 Inhibitor for Myelofibrosis with 62.8% Spleen Volume Response Rate

Company Drug

Leads Biolabs’ Partner Dianthus Selects Sjögren’s, Lupus, and Dermatomyositis as Priority Indications for Bifunctional Autoimmune Drug LBL-047 Following $1B Licensing Deal

Company Drug

Simcere Pharmaceutical Receives NMPA Clinical Trial Approval for LRRC15-Targeting ADC SIM0613, Backed by $1.06B Ipsen Global Licensing Deal

Company Deals

Alebund Pharmaceuticals Files for Hong Kong IPO, Leveraging CKD-Focused Portfolio with Commercialized Mircera and Late-Stage Hyperphosphatemia Candidates

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.